Skip to main content
  • Making investments to transform healthcare

    Supporting breakthrough therapies and medical products that benefit patients and the healthcare system.

  • Funding novel, disruptive life science innovations

    We provide capital and expertise to develop and market products with the potential to transform medical practice while building value for our investors.

  • Driving an industry breakthrough investment strategy

    Our approach sets us apart.

Our mission is to invest in the development of exciting life science products and the growth of companies to become innovative leaders in their market segment. As true partners, we work closely with our portfolio companies, striving to enable their ideas and bring new therapies and medical products to market. Our track record of successful collaborations highlights our partnership and value-building approach.

Our Approach

We have a unique two-pronged strategy. The first is the financing of innovative early-stage therapeutics through a single asset company approach that leverages our strategic relationship with global pharmaceutical firm Eli Lilly and Company. The second is to invest in differentiated commercial-stage medtech, diagnostics, and digital health products as well as late-stage therapeutics.

Our portfolio companies are a top priority.

  • >150

    life science investments

  • 900 M

    Euro in Assets
    Under Management

  • >100

    Years of Venture Capital and Industry Expertise of Team Members

    February 28-29, 2024

    17th Annual European Life Sciences CEO Forum

    TVM Capital Life Science will take part in the 17th Annual European Life Sciences CEO Forum February 28-29, 2024 in Zurich, Switzerland at the Hilton Zurich Airport Hotel.

    • Zurich, Switzerland at the Hilton Zurich Airport Hotel

    A strong team to support innovators

    Our team brings together a variety of skills and experience as well as a passion for the life sciences.